1. Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy.
- Author
-
Baxter L, Hopkins S, O'Connor KC, Pham MC, Nowak RJ, Monson NL, Blackburn K, Hibbs RE, Vernino S, and Noviello CM
- Subjects
- Humans, Female, Male, Middle Aged, Autonomic Nervous System Diseases immunology, Autonomic Nervous System Diseases diagnosis, Adult, Autoantibodies blood, Autoantibodies immunology, Autoimmune Diseases of the Nervous System immunology, Autoimmune Diseases of the Nervous System diagnosis, Autoimmune Diseases of the Nervous System blood, Chromatography, Gel methods, Receptors, Cholinergic immunology, Ganglia, Autonomic immunology
- Abstract
Autoimmune autonomic ganglionopathy (AAG) is a rare disease wherein autoantibodies target the ganglionic acetylcholine receptor (gAChR). Current diagnosis in the United States depends upon clinical symptoms and positive autoantibody detection using a radioimmunoprecipitation assay (RIA). Here we offer a proof-of-principle study on an alternative method, fluorescence-detection size-exclusion-chromatography (FSEC). We show FSEC can detect autoantibodies against gAChR from patient sera but not healthy controls or samples from other autoimmune diseases. We compare FSEC to RIA and find good correlation. We discuss potential advantages of using FSEC as an alternative or as a first-step diagnostic prior to pursuing existing methodologies., Competing Interests: Declaration of competing interest SV has received compensation as a consultant for argenx, Alterity, Amneal, Catalyst and LabCorp and has received research support from Quest Diagnostics (through a licensing contract). NM has received compensation from Genentech, Inc. as a member of the steering committee for CHIMES and is a co-founder of GenrAb, Inc., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF